Clinical Trials Browser

Phase 1/2 × Glioblastoma × TPI-287 × Clear all

NCT01933815 2023-02-22

Dose-Escalation Study of TPI 287 + Avastin Followed by Randomized Study of the Same Versus Avastin for Glioblastoma

Phase 1/2 Suspended

Glioblastoma

NCT01582152 2019-06-05

Phase I/II Bevacizumab Versus Bevacizumab Plus TPI 287 for Recurrent Glioblastoma

Phase 1/2 Terminated

12 enrolled 7 charts

Brain Neoplasms, Glioblastoma, Central Nervous System Neoplasms, Gliosarcoma